Curaleaf Holdings (CURLF) Income from Continuing Operations (2019 - 2026)
Curaleaf Holdings (CURLF) posted quarterly Income from Continuing Operations of 127334000.0 for Q1 2026, down 838.04% year-over-year from 17253000.0 in Q1 2025, and up 46.7% quarter-over-quarter from 238908000.0 in Q4 2025.
Curaleaf Holdings (CURLF) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Curaleaf Holdings' Income from Continuing Operations history runs 8 years deep, the most recent figure standing at 127334000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 838.04% year-over-year to 127334000.0; the TTM figure through Mar 2026 stood at 348152000.0 (down 56.13% YoY), while the FY2025 annual figure was 201903000.0, up 4.59% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 127334000.0, up from 238908000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 81059000.0 in Q2 2022, with the low at 63600000000.0 in Q4 2023.
- The 5-year median for Income from Continuing Operations is 12160000.0 (2025), against an average of 3776893882.35.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations slumped 26884.25% in 2023, then surged 1008.61% in 2024.
- Curaleaf Holdings' Income from Continuing Operations stood at 235693000.0 in 2022, then plunged by 26884.25% to 63600000000.0 in 2023, then surged by 99.57% to 275257000.0 in 2024, then grew by 13.21% to 238908000.0 in 2025, then jumped by 46.7% to 127334000.0 in 2026.
- Business Quant data shows CURLF's Income from Continuing Operations at 127334000.0 in Q1 2026, 238908000.0 in Q4 2025, and 5930000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | Curaleaf Holdings | 2.51 Bn | 2.42 Bn | 169.91 Mn | 12.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.49 Mn |
| Mar 31, 2026 | -127.33 Mn |
| Dec 31, 2025 | -238.91 Mn |
| Sep 30, 2025 | 5.93 Mn |
| Jun 30, 2025 | 12.16 Mn |
| Mar 31, 2025 | 17.25 Mn |
| Dec 31, 2024 | -275.26 Mn |
| Sep 30, 2024 | 20.78 Mn |
| Jun 30, 2024 | 14.23 Mn |
| Mar 31, 2024 | 28.60 Mn |
| Dec 31, 2023 | -63.60 Bn |
| Sep 30, 2023 | -4.09 Mn |
| Jun 30, 2023 | 17.31 Mn |
| Mar 31, 2023 | -3.15 Mn |
| Dec 31, 2022 | -235.69 Mn |
| Sep 30, 2022 | 58.52 Mn |
| Jun 30, 2022 | 81.06 Mn |
| Mar 31, 2022 | 21.39 Mn |
| Dec 31, 2021 | -5.24 Mn |
| Sep 30, 2021 | 63.74 Mn |